Vumerity Approved for RRMS in European Union

Vumerity Approved for RRMS in European Union

312302

Vumerity Approved for RRMS in European Union

The oral medication Vumerity (diroximel fumarate) has been approved by the European Commission to treat adults with relapsing-remitting multiple sclerosis (RRMS). “This approval is a significant step forward in improving treatment adherence for people living with relapsing MS, which can make a meaningful difference on treatment outcomes impacting their daily lives,” Maha Radhakrishnan, MD, chief medical officer at Biogen, which markets Vumerity, said in a press release. “The authorization of VUMERITY in the EU brings people…

You must be logged in to read/download the full post.